The Effects of Passive Heat Therapy in Patients With Chronic Kidney Disease

Last updated: October 7, 2024
Sponsor: Virginia Commonwealth University
Overall Status: Completed

Phase

N/A

Condition

Kidney Failure (Pediatric)

Kidney Failure

Kidney Disease

Treatment

Thermoneutral Control (CON)

Whole-body Passive Heat Therapy (HT)

Clinical Study ID

NCT05924919
HM20024906
22-01741
  • Ages > 18
  • All Genders

Study Summary

The objective of this proposal is to investigate the acute effects of whole-body passive heat therapy using far-infrared technology on vascular function, exercise capacity, and renal function in CKD patients. The central hypothesis is that an acute bout of whole-body passive heat therapy will be well-tolerated and lead to acute improvements in large blood vessel (macrovascular) function, small blood vessel (microvascular) function, and exercise capacity without significantly altering markers of acute kidney injury.

Eligibility Criteria

Inclusion

Inclusion Criteria for participants with CKD:

  • Age > 18 years old

  • Stage 2-4 CKD

Exclusion Criteria for participants with CKD:

  • Unstable medical conditions characterized by frequent or unpredictable biological, chemical, or psychological changes

  • Uncontrolled hypertension

  • Current fluid restrictions

  • End stage kidney disease or currently on dialysis treatment

  • Body weight < 40kg

  • Exhibits any contraindications to exercise as per ACSM guidelines

  • Regular tobacco and/or nicotine use

  • History of heat-related illness

  • Participates in regular exercise and/or sauna use

  • Current hormone replacement therapy

  • Pacemaker or electro-medical implant

  • Persons with or at risk of intestinal disorders including gastroporesis

  • History of diverticula

  • Persons who have undergone surgical procedures in the GI tract

  • Swallowing disorders

  • Chron's disease

  • Current pregnancy

  • Inability to provide informed consent

Study Design

Total Participants: 10
Treatment Group(s): 2
Primary Treatment: Thermoneutral Control (CON)
Phase:
Study Start date:
September 18, 2023
Estimated Completion Date:
March 19, 2024

Connect with a study center

  • Virginia Commonwealth University

    Richmond, Virginia 23220
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.